50k square feet is overkill for their current operation. I suggest reading up on RNA vaccines and compute Polystart in with antigen-coding potential. Many believe this technology was shelved, but I believe it has been further developed under the newly anointed scientific council that came aboard with the merger.
There’s an ongoing arms race for a COVID vaccine. Candidate’s potential for scaleability will prove to be valuable.
The company press release said it was a manufacturing facility. When I was researching the USAN last month there was activity on the POLYSTART trademark. Those dots connect.
News 
Market Data 
Discover 
AI
